Aventis Sues To Block Sanofi Bid; Warns That “Synergies” Would Hit Hard In U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
New Jersey lawsuit notes that Sanofi projects significant savings from merger but is downplaying impact in France and Germany. Aventis continues no-holds-barred defense against Sanofi bid.
You may also be interested in...
Sanofi Holds Line On Aventis Merger Price; Novartis Enters Talks
Sanofi will continue to evaluate the market reaction before deciding whether to sweeten its bid. Novartis accepts Aventis’ invitation to explore a deal; the move indicates France has expressed neutrality on an Aventis/Novartis combination.
Sanofi Holds Line On Aventis Merger Price; Novartis Enters Talks
Sanofi will continue to evaluate the market reaction before deciding whether to sweeten its bid. Novartis accepts Aventis’ invitation to explore a deal; the move indicates France has expressed neutrality on an Aventis/Novartis combination.
Aventis Offers Plan To Protect Shareholders From Sanofi Plavix Patent Risk
The Aventis board also votes to enter into negotiations with Novartis, thereby satisfying one of Novartis’ two prerequisites for commencing merger talks. Aventis will “pursue discussions” with French and German authorities to address their concerns about an Aventis/Novartis deal.